ACCESS TO XIIDRA MAY BE EASIER THAN YOU THINK
THIS DRY EYE AWARENESS MONTH AND BEYOND.
ACCESS TO XIIDRA MAY BE EASIER THAN YOU THINK
THIS DRY EYE AWARENESS MONTH AND BEYOND.
We know your patients with dry eye matter to you. Xiidra has comparable or better
coverage to Restasis for 88% of commercially insured patients1. Additionally, Xiidra is now covered for nearly 2 out of 3* Medicare Part D patients!2
We know your patients with dry eye matter to you. Xiidra has comparable or better
coverage to Restasis for 88% of commercially insured patients1. Additionally,Xiidra is now covered for nearly 2 out of 3* Medicare Part D patients!2
*Approximately 62% as of 5/17/22.
*Approximately 62% as of 5/17/22.
THE POWER OF EYE CARE TECHNICIAN RESOURCES
Dry eye disease (DED) awareness and early diagnosis matter. That’s why we created DryEyeTech.com as a hub for important resources, including downloadable tools, educational videos, and more. Take advantage of this great resource today.
THE POWER OF EYE CARE TECHNICIAN RESOURCES
Dry eye disease (DED) awareness and early diagnosis matter. That’s why we created DryEyeTech.com as a hub for important
resources, including downloadable tools, educational videos, and more. Take advantage of this great resource today.
NOVARTIS IS COMMITED TO EYE CARE TECHNICIANS AND PATIENTS.
NOVARTIS IS COMMITED TO EYE CARE TECHNICIANS AND PATIENTS.
Please ask your Novartis representative for
additional information and about how we can help.
Please ask your Novartis representative for
additional information and about how we can help.
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
•
Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
•
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
•
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
•
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
•
Safety and efficacy in pediatric patients below the age of 17 years have not been established.
References: 1. Data on file. Fingertip Formulary® with Payer Sciences business rules as of January 18, 2022.
2. Data on file. Fingertip Formulary® as of 05/2022. Novartis Pharmaceuticals Corp; May 2022. 3. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020.
4. US Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. 42nd edition. FDA website. Published 2022. Accessed April 27, 2022.
https://www.fda.gov/media/71474/download5. US Food and Drug Administration. FDA approves new medication for dry eye disease.
Published July 12, 2016. Accessed May 19, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-dry-eye-disease6. Novack GD, Asbell P, Barabino S, et al. TFOS DEWS II Clinical Trial Design Report. Ocul Surf. 2017;15(3):629-649.
If you prefer not to receive email communications related to Xiidra and the associated therapy areas, please click here.
If you have any questions concerning email or marketing communications from Novartis Pharmaceuticals Corporation, please call 1-888-NOW-NOVA (1-888-669-6682),
Monday through Friday, 8:30 AM through 5:00 PM ET.
For more information, please visit the Novartis Pharmaceuticals Corporation Privacy Policy.
